Journal
PHARMACEUTICAL BIOPROCESSING
Volume 1, Issue 1, Pages 71-87Publisher
OPEN ACCESS JOURNALS
DOI: 10.4155/PBP.13.8
Keywords
-
Categories
Funding
- Biomedical Research Council/Science and Engineering Research Council of A*STAR (Agency for Science, Technology and Research), Singapore.
Ask authors/readers for more resources
Clinical effectiveness has driven the commercial success of monoclonal antibody (mAb) products. Mammalian cells are currently the preferred system for large-scale production as the mAbs produced are biochemically similar to human forms. The cell line generation process is tedious and time-consuming as clones with high productivity, stable long-term expression and good product quality are rare occurrences. Cell line generation efficiency and mAb quality can be improved through host cell engineering, vector optimization and high-throughput clone selection. Targeted integration into predetermined sites on the chromosome is a promising new area being explored. This review covers existing technology and recent progress made in improving various aspects of the stable cell line generation process for mAb production.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available